Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs. Its internal program, PS433540, is a dual-acting angiotensin and endothelin receptor antagonist, which is in Phase I clinical development for the treatment of hypertension and diabetic nephropathy. The company’s product portfolio also includes CXCR2 antagonist, which is in Phase II clinical trials targeting chronic obstructive pulmonary disease; JAK3 Inhibitors for T-cell and cytokine mediated dermatologic and ocular diseases, such as psoriasis and dry eye; CCR1 Antagonists that is in Phase I clinical trials for treating rheumatoid arthritis and multiple sclerosis; Adenosine A2a Antagonists for parkinson’s disease; and ávâ3/ávâ5 Inhibitors, which is in Phase I clinical trials for oncology diseases. It has collaborations with Cephalon, Inc.; GlaxoSmithKline; N.V. Organon; Wyeth Pharmaceuticals Division; Schering Corporation; Schering-Plough, Ltd.; and Bristol-Myers Squibb Company. The company was founded in 1993. It was formerly known as Pharmacopeia Drug Discovery, Inc. and changed its name to Pharmacopeia, Inc. in May 2007. Pharmacopeia is based in Princeton, New Jersey.